Spring Bank Pharmaceuticals Nasdaq Listed Banner

News Releases

  • Webcast Image Webcast
    Research & Development (R&D) Day  (Replay)
    Thursday, December 06, 2018 12:00 pm EST
Toggle Summary Spring Bank Announces Positive Study Results from the Inarigivir ACHIEVE Trial
Maximum Reduction in HBV DNA up to 2.76log 10 and HBV RNA up to 5.0log 10 28% of Inarigivir Treated Patients Demonstrate a HBsAg Response with a Mean Reduction of 0.8log 10 and a Maximum Reduction of 1.4log 10 in Cohorts 1-3 of ACHIEVE Trial Two Additional Cohorts Added to HBV Clinical Program for
Toggle Summary Spring Bank Pharmaceuticals Reports Second Quarter Financial Results
Conference Call Scheduled for Thursday, August 2 at 8:00 a.m. EDT to Provide Corporate Update HOPKINTON, Mass. , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral
Toggle Summary Spring Bank to Present at Jefferies 2018 Global Healthcare Conference
HOPKINTON, Mass. , May 29, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports First Quarter Financial and Operational Results
Presented inarigivir 25 mg and 50mg cohorts from Phase 2 ACHIEVE trial in chronic hepatitis B patients at two scientific conferences Continues to advance SB 11285, a next-generation STING agonist, towards clinical trial HOPKINTON, Mass. , April 27, 2018 (GLOBE NEWSWIRE) -- Spring Bank
Toggle Summary Spring Bank Announces Expanded Inarigivir Data from the ACHIEVE Trial to Be Presented at The International Liver Congress™
*Results from full 24 weeks of dosing from the first two cohorts of Part A in the ongoing Phase 2 ACHIEVE trial in hepatitis B to be highlighted in oral and poster presentations *30% of patients in first two cohorts achieved >0.5log 10 reduction in HBsAg *Additional benefit of >0.5log 10 reduction
Toggle Summary Spring Bank Announces Presentation of Combined Inarigivir 25 mg and 50 mg 12 and 24 Week ACHIEVE Results Demonstrating Enhanced Anti-Viral Efficacy in HBeAg-Negative Patients
Data from the combined first two low dose inarigivir cohorts at weeks 12 and 24 with sequential Viread dosing demonstrate significant reductions in HBV DNA, HBV RNA and HBsAg Data to be presented at the APASL 2018 Annual Meeting HOPKINTON, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- Spring Bank
Toggle Summary Spring Bank to Present at Cowen & Company 38th Annual Health Care Conference
HOPKINTON, Mass. , March 09, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J.
Toggle Summary Spring Bank Pharmaceuticals Appoints Timothy Clackson, Ph.D., to its Board of Directors
Spring Bank strengthens Board of Directors with the addition of a prominent biopharma R&D veteran HOPKINTON, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of
Toggle Summary Spring Bank Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial and Operational Results
2017 highlighted by continued progress with global inarigivir clinical program for the treatment of chronic HBV and advancement of next-generation STING agonist candidate, SB 11285, towards the clinic Multiple potential development catalysts and data read-outs expected in 2018 HOPKINTON, Mass.
Toggle Summary Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21
Conference Call to be Held at 8:30am Eastern Time HOPKINTON, Mass. , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain